Urinary Tract Infection in Pregnancy

Status Not yet recruiting

Clinical Trial Summary

- to describe the profile of uropathogenic E coli from Egyptian pregnant women with UTIs and a symptomatic bacteriuria.

- to determine the susceptibility pattern of our local isolated UPEC strains which is essential for optimal management of UTI.

- to evaluate the different virulence genes in UPEC isolates and their association with antibiotic resistance.

- to track common UPEC serogroups.

- to investigate the biofilm formation and the relationship between virulence genes and biofilm formation in UPEC strains isolated from patients.

Clinical Trial Description

Urinary tract infection represents the most common bacterial infection in pregnancy and the third common cause of human infection after respiratory and intestinal infections. The infection can be life threatening and associated with serious complications. UTI can be associated with defined symptoms'symptomatic' or without symptoms 'asymptomatic'. Asymptomatic bacteriuria is defined as the presence of >100000 colony forming units/ml of urine of a single pathogen in two consecutive midstream clean catch urine specimen or on catheterization specimen from an individual without signs or symptoms associated with urinary or genital organs. Asymptomatic bacteriuria can lead to acute pyelonephritis in30%of pregnant women and complications such as early delivery, increase risk of hypertension, pre-eclampsia, low birth weight and postpartum endometritis. Ecoli accounts for most cases of symptomatic and asymptomatic bacteriuria in women, representing70 _90 %of the cases. The important virulence factors of uropathogenic ecoli can be broadly divided into two groups :bacterial cell surface factors and secreted factors. The emergence of drug resistant microorganism among Uropathogenic Escherichia coli strains increases the serious threat to global health. Ecoli often acquired genes coding for antibiotic resistance, beta-lactamase enzymes are the most frequent and play a key role, conferring resistance of bacteria to beta lactam antibiotic group such as penicillin and cephalosporins. Therefore, knowledge regarding local prevalence of uropathogenic ecoli and antimicrobial resistance is essential for optimal management of UTI. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04244526
Study type	Observational
Source	Assiut University
Contact	Noura Samir Hussein, Demonstrator
Phone	00201002606302
Email	Noura011456@med.au.edu.eg
Status	Not yet recruiting
Phase
Start date	March 1, 2020
Completion date	May 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04495699` - Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
Terminated	`NCT05254808` - EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care	Phase 3
Completed	`NCT03680612` - Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI	Phase 2
Completed	`NCT03282006` - Treating Pyelonephritis an Urosepsis With Pivmecillinam	Phase 4
Completed	`NCT03526484` - The Utility of Urinalysis Prior to In-Office Procedures	N/A
Completed	`NCT05397782` - Effects of Flourish on Recurrent Urinary Tract Infection	N/A
Completed	`NCT05018546` - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery	N/A
Completed	`NCT03687255` - Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections	Phase 3
Recruiting	`NCT05227937` - Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
Completed	`NCT02864420` - Hospitalization at Home: The Acute Care Home Hospital Program for Adults	N/A
Completed	`NCT03131609` - Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
Completed	`NCT01911143` - A Retrospective, Blinded Validation of a Host-response Based Diagnostics	N/A
Completed	`NCT01333254` - A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients	N/A
Terminated	`NCT00594594` - Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury	Phase 1
Completed	`NCT00216853` - A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection	N/A
Completed	`NCT00787085` - The Significance of Funguria in Hospitalized Patients	N/A
Completed	`NCT05719753` - The Effectiveness of a Bacteriophobic Coating on Urinary Catheters	N/A
Recruiting	`NCT05415865` - The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder	Phase 3
Not yet recruiting	`NCT05880329` - DIagnoSing Care hOme UTI Study
Recruiting	`NCT04615065` - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.